JP2013173782A5 - - Google Patents

Download PDF

Info

Publication number
JP2013173782A5
JP2013173782A5 JP2013097487A JP2013097487A JP2013173782A5 JP 2013173782 A5 JP2013173782 A5 JP 2013173782A5 JP 2013097487 A JP2013097487 A JP 2013097487A JP 2013097487 A JP2013097487 A JP 2013097487A JP 2013173782 A5 JP2013173782 A5 JP 2013173782A5
Authority
JP
Japan
Prior art keywords
fluoro
pregnan
pregnane
oxime
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013097487A
Other languages
English (en)
Japanese (ja)
Other versions
JP5657052B2 (ja
JP2013173782A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013173782A publication Critical patent/JP2013173782A/ja
Publication of JP2013173782A5 publication Critical patent/JP2013173782A5/ja
Application granted granted Critical
Publication of JP5657052B2 publication Critical patent/JP5657052B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013097487A 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 Expired - Fee Related JP5657052B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
US60/860,658 2006-11-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009537124A Division JP5386362B2 (ja) 2006-11-21 2007-11-20 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用

Publications (3)

Publication Number Publication Date
JP2013173782A JP2013173782A (ja) 2013-09-05
JP2013173782A5 true JP2013173782A5 (2) 2013-10-17
JP5657052B2 JP5657052B2 (ja) 2015-01-21

Family

ID=39429970

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009537124A Expired - Fee Related JP5386362B2 (ja) 2006-11-21 2007-11-20 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097486A Active JP5918170B2 (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097487A Expired - Fee Related JP5657052B2 (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097485A Pending JP2013173781A (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2015047791A Pending JP2015147774A (ja) 2006-11-21 2015-03-11 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009537124A Expired - Fee Related JP5386362B2 (ja) 2006-11-21 2007-11-20 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2013097486A Active JP5918170B2 (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013097485A Pending JP2013173781A (ja) 2006-11-21 2013-05-07 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
JP2015047791A Pending JP2015147774A (ja) 2006-11-21 2015-03-11 Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用

Country Status (16)

Country Link
US (9) US8580983B2 (2)
EP (4) EP2792681B1 (2)
JP (5) JP5386362B2 (2)
AU (1) AU2007322423C1 (2)
BR (2) BR122013033954B8 (2)
CA (2) CA2833976C (2)
DK (3) DK2097437T3 (2)
ES (3) ES2607852T3 (2)
HU (3) HUE033037T2 (2)
IN (1) IN2014DN02014A (2)
MX (1) MX2009005335A (2)
PL (3) PL2711371T3 (2)
PT (1) PT2097437E (2)
RU (1) RU2458065C2 (2)
SI (1) SI2097437T1 (2)
WO (1) WO2008063128A1 (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2097437T3 (en) * 2006-11-21 2015-06-29 Umecrine Cognition Ab THE USE OF PREGNANCY AND ANDROSTANOSTEROIDS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISEASES
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
HUE027298T2 (en) 2010-01-14 2016-10-28 Asarina Pharma Ab Pharmaceutical composition containing developed storage and dissolution properties containing 3-beta-hydroxy-5-alpha-pregnan-20-one
EP2566482A1 (en) * 2010-05-07 2013-03-13 Institut National de la Santé et de la Recherche Médicale Progesterone receptor antagonists and uses thereof
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
AU2013351190B2 (en) * 2012-11-28 2018-03-29 Alienor Farma 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
AU2015212606B2 (en) * 2014-01-29 2019-11-21 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016082789A1 (en) * 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AR103384A1 (es) * 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
PL3319611T3 (pl) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
MX382122B (es) 2015-07-06 2025-03-13 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
DK4105223T3 (da) 2016-10-18 2025-07-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3579842A4 (en) 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
JP7179739B2 (ja) 2017-02-10 2022-11-29 アサリナ ファーマ アーベー 医学的治療における使用のための3-β-ヒドロキシ-5-α-プレグナン-20-オン
BR112020010519A2 (pt) 2017-11-27 2020-10-20 Umecrine Cognition Ab formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
MX2020010219A (es) 2018-04-05 2020-11-09 Asarina Pharma Aps Antagonistas de gaba-a para tratar trastornos por abstinencia de sustancia.
CN116589521B (zh) 2019-01-08 2025-07-11 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
US20250387409A1 (en) 2021-11-10 2025-12-25 Umecrine Cognition Ab 3-beta-hydroxy-3-alpha-ethyl steroids for modulation of the alpha-3 subtype of the gabaa receptor
EP4429669A1 (en) 2021-11-10 2024-09-18 Umecrine AB Steroid as a modulator of gabaa receptor
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
EP4389129A1 (en) * 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia
WO2025252724A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone
WO2025252725A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) * 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) * 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
KR100338287B1 (ko) * 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
FI972202L (fi) * 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
RU2194712C2 (ru) 1995-06-06 2002-12-20 Коукенсис, Инк. НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
CN1270718C (zh) 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
WO1999052532A1 (en) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
FR2831441B1 (fr) 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (en) 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
WO2006054938A1 (en) * 2004-11-18 2006-05-26 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders
DK2097437T3 (en) 2006-11-21 2015-06-29 Umecrine Cognition Ab THE USE OF PREGNANCY AND ANDROSTANOSTEROIDS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISEASES
EP2566482A1 (en) 2010-05-07 2013-03-13 Institut National de la Santé et de la Recherche Médicale Progesterone receptor antagonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2013173782A5 (2)
JP2013173781A5 (2)
JP2015147774A5 (2)
JP2015528502A5 (2)
JP2016028092A5 (2)
JP2012107057A5 (2)
JP2016000169A5 (2)
JP2016065085A5 (2)
NO2024009I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
JP2015525757A5 (2)
JP2015081257A5 (2)
JP2016502162A5 (2)
JP2015503422A5 (2)
JP2014501485A5 (2)
JP2015125255A5 (2)
JP2014156468A5 (2)
JP2015504870A5 (2)
JP2013543797A5 (2)
JP2017005051A5 (2)
JP2017508572A5 (2)
JP2011170856A5 (2)
JP2013253099A5 (2)
HUE055468T2 (hu) Új vegyület és gyógyszerészetileg elfogadható sója
JP2013536184A5 (2)
JP2015537124A5 (2)